Article

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancer

2022-09-25

Abstract excerpt

HER2 mutations drive the growth of a subset of breast cancers and are targeted with HER2 tyrosine kinase inhibitors (TKIs) such as neratinib. However, acquired resistance is common and limits the durability of clinical responses. Most HER2 -mutant breast cancers progressing on neratinib-based therapy acquire secondary mutations in HER2 . Apart from the HER2 T798I gatekeeper mutation, whether these secondary H...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 61f863d8-6356-52d4-90ed-ab0bc40ff214
DOI: 10.1101/2022.09.23.509246

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerDOI 10.1101/2022.09.23.509246Read

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.Semantic proximity Read

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Semantic proximity Read

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Semantic proximity Read

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failureSemantic proximity Read

Activating HER2 mutations as emerging targets in multiple solid cancersSemantic proximity Read

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast CancerSemantic proximity Read

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.Semantic proximity Read

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read